Navigation Links
Dendreon Secures $130 Million Committed Equity Financing Facility
Date:10/12/2007

SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has obtained a committed equity financing facility under which it may sell up to $130 million of its registered common stock to Azimuth Opportunity, Ltd. over an 18-month period. Dendreon is not obligated to utilize any of the $130 million facility and remains free to enter into and consummate other equity and debt financing transactions.

Dendreon will determine, at its sole discretion, the timing, dollar amount and floor price per share of each draw under this facility, subject to certain conditions. The number and price of shares sold in each draw are determined by a contractual formula, whereby Dendreon will issue shares to Azimuth when and if Dendreon elects to use the facility at a small discount to the volume weighted average price of Dendreon's common stock over a preceding period of trading days. Reedland Capital Partners will act as placement agent and receive a fee for its services at the time of any draw under the facility. Any shares sold under this facility will be sold pursuant to a shelf registration statement declared effective by the Securities and Exchange Commission on May 25, 2007.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, market demand for Dendreon's common stock and events and developments affecting Dendreon's business and prospects. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
2. Perscitus Biosciences secures $250K Commerce loan
3. ProCertus BioPharm secures $2.3M in financing
4. Mirus Bio secures $900K grant to develop research tool
5. BioSystem Development secures angel funding
6. TrafficCast secures $1 million line of credit
7. Medical College secures $9.7M research grant
8. Wausau start up secures $560K for GPS maps
9. Platypus Technologies secures $450K SBIR grant
10. nPoint Secures Second Round of Funding
11. Congresswoman Baldwin secures Federal Funds for UW-Rock County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ... device industries, announced today that they will be receiving 3 awards at the 2019 ... WCCT received 2 awards in the categories of overall Quality and Compatibility (Access to ...
(Date:5/31/2019)... ... 2019 , ... A study released today in STEM CELLS ... sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) to treat ... into the injured kidney, where it helped restore function and regenerate injured tissue. ...
(Date:5/14/2019)... ... May 13, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is ... redesigned website aims to improve LDA’s ability to communicate directly with the marketplace; ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the world ... Negative Response vision test, a new full field electroretinography (ffERG) protocol designed ... 6.3 million Americans will have glaucoma, with black Americans having the highest prevalence ...
Breaking Biology Technology:
(Date:7/9/2019)... ... 2019 , ... On June 27, 2019, the Danish Maritime ... two Danisco amylase patent applications (EP2859097 and EP2825643). The court reasoned that Novozymes’ ... without merit and awarded costs to Danisco. , “Testimony from the trial ...
(Date:6/20/2019)... ... 2019 , ... The half-million dollars in Alzheimer’s disease (AD) ... the possibly millions of dollars of “high priority” grants now offered by the ... affirmation” of the need to investigate more thoroughly the possible roles of germs ...
(Date:6/14/2019)... ... June 14, 2019 , ... Molecular diagnostics segment is the fastest-growing segment within ... 2019. Major segments that are expected to drive the growth are infectious diseases, ... as segments in Kalorama’s The World Molecular Diagnostics Market, 8th Edition . , ...
Breaking Biology News(10 mins):